Breaking News Instant updates and real-time market news.

VSAT

ViaSat

$87.89

-1.63 (-1.82%)

, DECK

Deckers Brands

$147.27

-2.94 (-1.96%)

18:50
05/23/19
05/23
18:50
05/23/19
18:50

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Viasat (VSAT) up 7.0%... Deckers (DECK) up 4.5%... DXC Technology (DXC) up 2.9%... HP Inc (HPQ) up 2.1%... Intuit (INTU) up 2.0%. ALSO HIGHER: Novocure (NVCR) up 4.2% after FDA approval of its NovoTTF-100LTM system in combination with pemetrexed... CenturyLink (CTL) up 2.7% after disclosing CEO bought 50K shares. DOWN AFTER EARNINGS: Autodesk (ADSK) down 8.7%... Lionsgate (LGF.A) down 3.8%... Ross Stores (ROST) down 3.3%... Splunk (SPLK) down 2.5%... HP Enterprise (HPE) down 1.2%. ALSO LOWER: Dynavax (DVAX) down 7.9% after announcing strategic restructuring to focus on vaccine business... RTI Surgical (RTIX) down 3.6% after equity offering. Movers as of 18:30ET.

VSAT

ViaSat

$87.89

-1.63 (-1.82%)

DECK

Deckers Brands

$147.27

-2.94 (-1.96%)

DXC

DXC Technology

$52.00

-2.5 (-4.59%)

HPQ

HP Inc.

$19.20

-0.095 (-0.49%)

INTU

Intuit

$241.30

-6.22 (-2.51%)

NVCR

Novocure

$49.40

-1.92 (-3.74%)

CTL

CenturyLink

$9.66

-0.29 (-2.91%)

ADSK

Autodesk

$169.64

-4.47 (-2.57%)

LGF.A

Lionsgate

$15.96

-0.06 (-0.37%)

ROST

Ross Stores

$94.54

-0.06 (-0.06%)

SPLK

Splunk

$128.68

-7.12 (-5.24%)

HPE

HP Enterprise

$14.33

-0.21 (-1.44%)

DVAX

Dynavax

$6.36

(0.00%)

RTIX

RTI Surgical

$4.40

-0.08 (-1.79%)

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 10

    Jun

  • 12

    Jun

  • 13

    Jun

  • 17

    Jun

  • 09

    Jul

VSAT ViaSat
$87.89

-1.63 (-1.82%)

04/26/19
RILY
04/26/19
NO CHANGE
Target $145
RILY
Buy
ViaSat price target raised to $145 from $89 at B. Riley FBR
B. Riley FBR analyst Mike Crawford raised his price target for ViaSat to $145 from $89 citing bandwidth economics and the company's growth. He reiterates a Buy rating on the shares.
02/15/19
RAJA
02/15/19
NO CHANGE
Target $81
RAJA
Outperform
ViaSat price target raised to $81 from $73 at Raymond James
Raymond James analyst Ric Prentiss raised his price target on ViaSat shares to $81 from $73 after the company reported what he called "strong" EBITDA in Q3 in its Satellite Services, Government Systems, and Commercial Networks segments. Noting that management said it expects the company to be free cash flow positive "a couple of years" after the first VSAT-3 launch, Prentiss keeps an Outperform rating on ViaSat shares.
06/11/18
RBCM
06/11/18
NO CHANGE
Target $45
RBCM
Underperform
ViaSat price target lowered to $45 from $52 at RBC Capital
RBC Capital analyst Wilton Fry lowered his price target on ViaSat to $45 and kept his Underperform Rating, saying that despite the company's recent reset of financial covenants, it is "rapidly" running out of headroom. The analyst points to the "dampened" operating leverage from Viasat's SAC costs, the Eutelsat withdrawal from ViaSat-3b, and the "likely end to its recent working capital tailwind", which may require the company to seek an equity raise.
05/31/18
WBLR
05/31/18
NO CHANGE
WBLR
Outperform
ViaSat shares positioned well for long-term returns, says William Blair
All of ViaSat's divisions, not just the Government segment, should start performing "like all-stars" going forward, William Blair analyst Louie DiPalma tells investors in a research note titled "Expect More 'Warriors' and Less 'Cavs' in the Second Half of the Fiscal Year." He expects ViaSat's financials to show "significant improvement" in the December quarter and keeps an Outperform rating on the shares. The stock is positioned well for long-term shareholder returns, the analyst contends.
DECK Deckers Brands
$147.27

-2.94 (-1.96%)

05/21/19
BOFA
05/21/19
UPGRADE
BOFA
Buy
Deckers Brands upgraded to Buy from Neutral at BofA/Merrill
05/14/19
05/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Coca-Cola (KO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying the company's growth outlook is "clearly superior" relative to the packaged goods space, but this is not reflected in the current share price. 3. Capital One (COF) upgraded to Buy from Hold at Jefferies with analyst John Hecht saying he expects the stock to benefit from "bigger payouts and improving efficiencies." 4. Deckers Brands (DECK) upgraded to Positive from Neutral at Susquehanna. 5. Agco (AGCO) upgraded to Overweight from Neutral at JPMorgan with analyst Ann Duignan saying given Agco's limited exposure to the U.S. row crop sector, the recent sell-off in the shares is overdone. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/21/19
BOFA
05/21/19
UPGRADE
Target $180
BOFA
Buy
Deckers Brands upgraded to Buy on EPS upside at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Rafe Jadrosich upgraded Deckers Brands to Buy from Neutral as he sees upside to the consensus EPS view given the strength of the Hoka brand and the company's stock buybacks. Jadrosich, who forecasts double-digit average EPS growth over the next two years, noted that his FY20 and FY21 EPS estimates for Deckers are roughly 6% and 13% ahead of consensus, respectively. He raised his price target on Deckers shares to $180 from $150.
05/21/19
05/21/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kroger (KR) upgraded to Outperform from Market Perform at Bernstein with analyst Brandon Fletcher saying its market valuation has had a tough start this year and that he believes it is at a level where short-term and long-term capabilities are not being completely factored in. 2. TripAdvisor (TRIP) upgraded to Buy from Hold at Needham and to Neutral from Sell at Guggenheim. 3. Stanley Black & Decker (SWK) upgraded to Buy from Hold at Zelman. 4. Deckers Brands (DECK) upgraded to Buy from Neutral at BofA/Merrill with analyst Rafe Jadrosich saying he sees upside to the consensus EPS view given the strength of the Hoka brand and the company's stock buybacks. 5. Just Energy (JE) upgraded to Speculative Buy from Hold at Canaccord. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DXC DXC Technology
$52.00

-2.5 (-4.59%)

02/11/19
RHCO
02/11/19
NO CHANGE
Target $72
RHCO
Hold
DXC Technology price target raised to $72 from $65 at SunTrust
SunTrust analyst Frank Atkins raised his price target on DXC Technology (DXC) to $72 after its "solid" Q3 results and guidance. The analyst says the company's margins expanded and its sales trajectory has improved, even though he sees a more favorable tax rate driving some of its earnings beat. Atkins keeps his Hold rating on DXC Technology, citing uncertainty related to Luxoft (LXFT) integration risk.
05/21/19
BMOC
05/21/19
NO CHANGE
Target $70
BMOC
Outperform
DXC Technology price target lowered to $70 from $82 at BMO Capital
BMO Capital analyst Keith Bachman lowered his price target on DXC Technology to $70, adjusting his model to reflect his rolled out 6-times enterprise value to expected FY21 EBITDA multiple. The analyst also keeps his Outperform rating on the stock, saying its future value will be sustained by the company's growing revenues and realized cost savings. Bachman adds that he expects DXC Technology to grow its revenue by up to 1% in the second half of FY20 and in FY21, with even "modest" organic growth being well received by investors.
04/22/19
GSCO
04/22/19
DOWNGRADE
GSCO
Buy
DXC Technology downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst James Schneider removed DXC Technology from the Conviction Buy List and maintained a Buy rating saying shares could remain range bound near-term given revenue declines over the next two quarters given the pending acquisition of Luxoft. The analyst continues to see compelling value in shares and believes the Street's earnings estimates are too low.
05/20/19
KEYB
05/20/19
NO CHANGE
Target $88
KEYB
Overweight
DXC Technology price target lowered to $88 from $97 at KeyBanc
KeyBanc analyst Arvind Ramnani lowered his price target for DXC Technology to $88 from $97, while reiterating an Overweight rating on the shares. The analyst notes that DXC has largely underperformed the S&P 500 year to date as investors are skeptical about its transition to a revenue growth story and Street expectations have been mismanaged. Despite negative investor sentiment, Ramnani finds risk/reward to be attractive at these levels, with DXC having one of the lowest valuations in tech.
HPQ HP Inc.
$19.20

-0.095 (-0.49%)

05/14/19
WOLF
05/14/19
DOWNGRADE
Target $21
WOLF
Peer Perform
HP Inc. downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded HP Inc to Peer Perform from Outperform saying VAR checks indicate printing demand will remain under pressure thru the rest of F19, with no major positive catalyst ahead.
04/17/19
SBSH
04/17/19
NO CHANGE
Target $44
SBSH
Buy
Xerox could be strategic acquisition target after EFI deal, says Citi
Citi analyst Jim Suva points out that the buyout of Electronics for Imaging (EFII) by private equity contains a 45 day "go-shop" period. With the print industry maturing, the analyst believes both HP Inc. (HPQ) and XRX (XRX) will now "more aggressively look" at Electronics for Imaging as a strategic asset in terms of revenue growth, earnings accretion, and cash flow. Further, Xerox could be a strategic acquisition for private equity or HP given its annual cash flow of $1B-plus and cost structure that could be significantly reduced, Suva tells investors in a research note. The analyst keeps a Buy rating on Electronics for Imaging and boosted his price target for the shares to $44.
04/11/19
04/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Hold at HSBC. 2. Apple (AAPL), Dell Technologies (DELL), and HP Inc. (HPQ) initiated with a Neutral at Credit Suisse. 3. Yeti (YETI) initiated with an Outperform at Cowen. 4. CVS Health (CVS) initiated with a Market Perform at BMO Capital. 5. Canadian Solar (CSIQ) assumed with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
FBCO
04/11/19
INITIATION
Target $21
FBCO
Neutral
HP Inc. initiated with a Neutral at Credit Suisse
Credit Suisse analyst Matt Cabral started coverage of HP Inc. with a Neutral rating and a $21 price target. The analyst sees supplies as a "key concern" following the disappointing inventory reset, despite "steady" gains on PC share and free cash flow.
INTU Intuit
$241.30

-6.22 (-2.51%)

04/02/19
KEYB
04/02/19
NO CHANGE
Target $285
KEYB
Overweight
Intuit price target raised to $285 from $255 at KeyBanc
KeyBanc analyst Josh Beck raised his price target for Intuit to $285 from $255, while reiterating an Overweight rating on the shares. The analyst has analyzed his proprietary Key First Look Data of about 1.8M unique credit/debit cards and based on quarter to date trends, his data indicates consumer/tax ARPT is growing 6% year over year. Beck expects it to finish this season up closer to 8%.
04/11/19
GUGG
04/11/19
NO CHANGE
Target $310
GUGG
Buy
Intuit price target raised to $310 on TurboTax Live potential at Guggenheim
Guggenheim analyst Ken Wong said he sees TurboTax Live having the potential to drive $5B of Consumer revenue in 2022 and $7B in 2025 for Intuit in an upside scenario. His test drive of Live and interaction with TurboTax representatives suggest demand is strong, noted Wong, who raised his price target on Intuit shares to $310 from $260, citing the "transformative potential" of TurboTax Live. He maintains a Buy rating on Intuit.
04/12/19
DBAB
04/12/19
NO CHANGE
Target $280
DBAB
Buy
Intuit price target raised to $280 from $270 at Deutsche Bank
Deutsche Bank analyst Michael Turrin raised his price target for Intuit to $280 from $270 after surveying 1,000 U.S. tax filers. Despite changes to the tax code, Filers appear to be mostly maintaining the status quo and sticking with whatever method they used last year, Turrin tells investors in a research note. He points out that 54% of respondents using do-it-yourself versus 52% last year. The analyst sees 2019 as "another big year" for TurboTax average revenue per user expansion and keeps a Buy rating on Intuit.
04/17/19
GUGG
04/17/19
NO CHANGE
GUGG
Buy
Intuit saw significant uptick in TurboTax demand, says Guggenheim
Guggenheim analyst Ken Wong kept his Buy rating on Intuit coming out of the final weekend of the 2019 tax season, saying that its TurboTax platform saw a "significant uptick in demand relative to interactions in late February and throughout March." The analyst states that the platform had weekend wait times of 45 minutes to 2 hours, while his interactions with Intuit accountants indicated that they were "asked to take on additional shifts to meet customer demand with the increase in capacity."
NVCR Novocure
$49.40

-1.92 (-3.74%)

09/25/18
MZHO
09/25/18
NO CHANGE
Target $58
MZHO
Buy
Novocure shares attractive at current levels, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Novocure with a $58 price target after hosting meetings with management. The analyst believes "significant growth" remains for NovoCure over time as the Optune technology is applied in multiple solid cancer indications. The shares are attractive at current levels relative to the company's growth opportunity, Yang tells investors in a research note.
10/26/18
MZHO
10/26/18
NO CHANGE
Target $51
MZHO
Buy
Novocure post-earnings selloff 'way overdone,' says Mizuho
Mizuho analyst Difei Yang views yesterday's post-earnings selloff in shares of Novocure as "way overdone." The company's Q3 results were in-line with expectations and the investor reaction was overly focused on negative quarter-over-quarter U.S. prescription growth, Yang tells investors in a research note. The analyst points out that active patients on Optune continued to grow during the quarter, although at a smaller pace in the U.S. She lowered her price target for the shares to $51 from $58 and reiterates a Buy rating on Novocure.
11/02/18
WELS
11/02/18
DOWNGRADE
Target $36
WELS
Market Perform
Novocure downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen downgraded Novocure to Market Perform and lowered his price target for the shares to $36 from $41. The analyst cites another quarter of flattish U.S. prescription trends for the downgrade and sees a lack of major catalysts heading into 2019. While year-over-year Optune growth has been solid, there has been little sequential volume growth in the U.S. during 2018 despite positive data and treatment guideline upgrade in the past 12 months, Biegelsen tells investors in a research note. And he sees no clear catalyst in 2019 that would meaningfully accelerate its penetration rate.
03/19/19
RHCO
03/19/19
INITIATION
Target $50
RHCO
Hold
Novocure initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert started Novocure with a Hold rating and $50 price target. The analyst believes the shares now reflect investor optimism for continued growth of Optune in glioblastoma, Medicare coverage for Optune, a mesothelioma approval, and the potential for Optune to have utility in larger indications. While Gilbert does not see enough near-term upside for a Buy rating, he believes Novocure has the potential for "significant" upside over the next few years.
CTL CenturyLink
$9.66

-0.29 (-2.91%)

05/23/19
GUGG
05/23/19
UPGRADE
Target $10
GUGG
Neutral
CenturyLink upgraded to Neutral on valuation at Guggenheim
Guggenheim analyst Mike McCormack upgraded CenturyLink to Neutral from Sell with the shares below his price target of $10. Despite the continued challenging fundamental backdrop, CenturyLink shares offer a more balanced risk/reward after declining 34% year-to-date, McCormack tells investors in a research note. While the analyst finds it unlikely that the company's Consumer business will get sold, he believes management is appropriately running the unit for cash as de-levering continues.
05/09/19
SBSH
05/09/19
UPGRADE
SBSH
Neutral
CenturyLink upgraded to Neutral from Sell at Citi
Citi analyst Michael Rollins upgraded CenturyLink to Neutral from Sell.
05/23/19
GUGG
05/23/19
UPGRADE
GUGG
Neutral
CenturyLink upgraded to Neutral from Sell at Guggenheim
05/09/19
SBSH
05/09/19
UPGRADE
SBSH
Neutral
CenturyLink upgraded to Neutral on cash flow, cost cutting at Citi
As previously reported, Citi analyst Michael Rollins upgraded CenturyLink (CTL) to Neutral from Sell. While he said the company reported "another mixed quarter" and he thinks the pace of revenue decline should continue to depress the multiple, the company's "aggressive" cost cutting, cash flow and dividend yield should provide downside support, Rollins tells investors. He remains cautious on whether CenturyLink can create value by separating its consumer business, he added. Rollins recommends that investors seeking dividends in Telco buy AT&T (T) and Verizon (VZ) instead.
ADSK Autodesk
$169.64

-4.47 (-2.57%)

04/11/19
04/11/19
INITIATION
Target $200

Buy
Autodesk initiated with a Buy at Mizuho
As previously reported, Mizuho analyst Matthew Broome initiated Autodesk with a Buy rating and a price target of $200. The analyst is positive on the company building its value proposition "beyond its traditional design base into lifecycle management, construction, and generative design", while expanding penetration with current customers and the overall total addressable market. Broome believes that Autodesk has multiple catalysts given its "strong upsell opportunities to Industry Collections, an improving direct sales mix, and more targeted digital marketing."
04/12/19
04/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Redfin (RDFN) initiated with an Outperform at Wedbush. 2. Autodesk (ADSK) initiated with a Buy at Mizuho. 3. Upwork (UPWK) initiated with a Buy at BTIG. 4. Otter Tail (OTTR) initiated with a Buy at Maxim. 5. Disney (DIS) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/21/19
RBCM
05/21/19
NO CHANGE
Target $200
RBCM
Outperform
Autodesk Q1 to mark strong start to FY20, says RBC Capital
RBC Capital analyst Matthew Hedberg kept his Outperform rating and $200 price target on Autodesk ahead of its Q1 results. The analyst cites the "positive" findings of his survey of the company's channel partners, saying 87% of respondents indicated that the quarter tracked "in line with or above plan" and 90% believed that the company's economic trends were "neutral to positive". Hedberg further states that Autodesk's most recent Analyst Day reflected the company's "encouraging" growth opportunity and resilience to macro headwinds.
04/11/19
MZHO
04/11/19
INITIATION
Target $120
MZHO
Autodesk initiated with a Buy at Mizuho
LGF.A Lionsgate
$15.96

-0.06 (-0.37%)

04/29/19
04/29/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lionsgate (LGF, LGF.A, LGF.B) downgraded to In-Line from Outperform at Imperial Capital with analyst David Miller citing additional promotional expenses related to the Starz international rollout. 2. Occidental Petroleum (OXY) downgraded to Hold from Buy at Jefferies with analyst Jason Gammel saying the company's hostile counter-offer for Anadarko (APC) is a "risky but perhaps necessary move against a better-capitalized bidder for a company that rejected its initial overtures." 3. CVS Health (CVS) downgraded to Neutral from Outperform at Credit Suisse with analyst A.J. Rice saying the stock faces a transitional year as it tries to drive seismic changes in healthcare. 4. Intel (INTC) downgraded to Hold from Buy at Argus with analyst Jim Kelleher citing the company's Q1 earnings miss and reduced FY19 outlook that reflected the company's Data Center Group weakness, which he calls "the linchpin of growth." 5. 3M (MMM) downgraded to Hold from Buy at Gordon Haskett with analyst John Inch downgraded saying his concerns extend beyond the company's Q1 earnings miss and steep guidance reduction. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/14/19
WEDB
01/14/19
NO CHANGE
Target $200
WEDB
Outperform
China price cuts, content M&A to lay groundwork for Apple's future, says Wedbush
Wedbush analyst Daniel Ives believes Apple (AAPL) needs to aggressively cut prices in China on XR and pull forward what he estimates is roughly 15M-20M iPhones that would otherwise sit idle waiting for the next release, or worst case, move to lower priced competition. Additionally, with services the linchpin of the Apple story moving forward, there needs to be serious contemplation within Cupertino around significant content acquisitions to drive services over the coming years, he contends. Ives sees A24, Lionsgate (LGF.A; LGF.B), and Sony Pictures (SNE) among the highest probability M&A targets, Viacom (VIA;VIAB)/CBS(CBS), and MGM Studios among the medium probability M&A targets, and Netflix (NFLX), Disney (DIS), and Gaming platform/video game publishers among the low probability M&A targets. The analyst reiterates an Outperform rating and $200 price target on Apple shares.
02/11/19
BRRR
02/11/19
NO CHANGE
Target $21
BRRR
Outperform
Lionsgate price target lowered to $21 from $27 at Barrington
Barrington analyst James Goss lowered his price target for Lionsgate to $21 and keeps an Outperform rating on the shares. The company's content investments have been important in "dramatically" reducing churn following the conclusion of its premiere series Power, Goss tells investors in a research note. This, along with promotional efforts, enabled subscriber levels to remain sequentially flat in Q3, compared to a 500,000 sequential decline in the year-ago period, the analyst points out. His new price target reflects a target multiple of about 10 times his fiscal 2020 OIBDA estimates.
04/29/19
IMPC
04/29/19
DOWNGRADE
Target $16
IMPC
In-Line
Lionsgate downgraded to In-Line from Outperform at Imperial Capital
Imperial Capital analyst David Miller downgraded Lionsgate (LGF.B) to In-Line from Outperform and cut his price target for the shares to $16 from $24. The shares closed Friday up 17c to $14.37. The analyst decreased his fiscal 2019 EBITDA and earnings estimates due to additional promotional expenses related to the Starz international rollout. Further, he lowered his 2020 estimates due to concerns that Lionsgate may guide down, due in large part to recent film performance. Due to the disappointing performance of Hellboy in the theatrical window, and "lukewarm" reviews thus far for Long Shot, the Seth Rogan comedy to be released on May 3, there is a "fairly decent chance" Lionsgate may end up falling short of its guidance, Miller tells investors in a research note.
ROST Ross Stores
$94.54

-0.06 (-0.06%)

05/14/19
05/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with a Buy, $3 price target at BTIG. 2. Ross Stores (ROST) and TJX (TJX) initiated with an Outperform at Baird. 3. Elastic (ESTC) initiated with a Hold at Stifel. 4. CytomX Therapeutics (CTMX) initiated with an Overweight at Cantor Fitzgerald. 5. FIS (FIS) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/19
BARD
05/14/19
INITIATION
Target $108
BARD
Outperform
Ross Stores initiated with an Outperform at Baird
Baird analyst Mark Altschwager initiated Ross Stores with an Outperform rating and $108 price target, telling investors in a research note that "there is a lot to like" about the off-price retailer, including "strong" management, "consistent" comp growth and "healthy" margins. While recent executive turnover adds a risk factor, the analyst says he sees a "deep bench" and thinks shares offer a good "deal" for investors looking for a high-quality/growth retailer trading at reasonable valuation.
05/13/19
BARD
05/13/19
INITIATION
Target $108
BARD
Outperform
Ross Stores initiated with an Outperform at Baird
Baird analyst Mark Altschwager initiated Ross Stores with an Outperform and $108 price target.
05/06/19
LOOP
05/06/19
NO CHANGE
Target $200
LOOP
Buy
Burlington Stores price target raised to $200 from $185 at Loop Capital
Loop Capital analyst Laura Champine raised her price target on Burlington Stores (BURL) to $200 and kept her Buy, citing the appointment of Michael O'Sullivan as new CEO, whom she considers to be a "great fit". The analyst cites O'Sullivan's experience at Ross Stores (ROST), where he contributed to its ladies' apparel and home goods categories performance - areas where Burlington Stores "remains underpenetrated." Champine lowers her Q1 comps forecast to flat from 2% but also raises her long-term estimate to 2.5% from 2%.
SPLK Splunk
$128.68

-7.12 (-5.24%)

05/16/19
PIPR
05/16/19
NO CHANGE
Target $160
PIPR
Overweight
Splunk should be bought ahead of Q1 results, says Piper Jaffray
Piper Jaffray analyst Alex Zukin says his channel checks suggest a favorable start to Splunk's 2019, with security continuing to drive customer activity. The analyst sees a 5% beat when the company reports on May 23, in line with previous Q1's, and his research continues to suggest a "robust demand environment and solid fundamentals." He would be adding to positions in front of the quarter and reiterates an Overweight rating on Splunk shares with a $160 price target.
05/06/19
MSCO
05/06/19
INITIATION
Target $47
MSCO
Equal Weight
PagerDuty initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Sanjit Singh started PagerDuty (PD) with an Equal Weight rating and $47 price target, stating that he views the company as the leader in an over $25B opportunity to employ sophisticated machine learning to detect major IT outages as they occur and mobilize the human response needed. However, he also believes that 30%+ revenue growth thru 2020 looks factored in at the stock's current levels. Singh calls out growing competition as the key risk facing PagerDuty with Splunk (SPLK) and Atlassian (TEAM) having entered the market in 2018 via acquisitions of PagerDuty competitors.
03/14/19
MZHO
03/14/19
INITIATION
Target $150
MZHO
Buy
Mizuho sees 'very healthy' duration-adjusted growth for Splunk, starts at Buy
Mizuho analyst Gregg Moskowitz last night initiated coverage of Splunk with a Buy rating and $150 price target. The company's value proposition "remains significantly differentiated," and it is "very well-positioned" to continue growing at a high rate, Moskowitz tells investors in a research note. Contrary to the bear thesis, Splunk's duration-adjusted growth is "very healthy," adds the analyst.
03/13/19
MZHO
03/13/19
INITIATION
Target $150
MZHO
Buy
Splunk initiated with a Buy at Mizuho
Mizuho analyst Gregg Moskowitz initiated Splunk with a $150 price target.
HPE HP Enterprise
$14.33

-0.21 (-1.44%)

05/20/19
CHLM
05/20/19
DOWNGRADE
Target $35
CHLM
Hold
Cray downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Chad Bennett downgraded Cray (CRAY) to Hold from Buy and lowered his price target on the shares to $35 from $36 after HP Enterprise (HPE) announced that it has entered into an agreement to purchase the company for $35.00 per share in cash, totaling $1.3B net of cash. The analyst believes the possibility of another buyer coming in over the top is fairly low, but notes that the price is "too low" based on the opportunities Cray has in front of it over the next few years. Furthermore, Bennett believes there would be a number of interested parties in Cray including Microsoft (MSFT), Dell (DELL), Intel (INTC), Alphabet (GOOG), Amazon (AMZN), and potentially IBM (IBM).
04/11/19
FBCO
04/11/19
INITIATION
Target $14
FBCO
Underperform
HP Enterprise initiated with an Underperform at Credit Suisse
Credit Suisse analyst Matt Cabral started coverage of HP Enterprise with an Underperform rating and a $14 price target. The analyst cited fading IT spending tailwinds, with focus returning to building risks on largest and high-margin segments.
05/17/19
CHLM
05/17/19
DOWNGRADE
CHLM
Hold
Craig-Hallum downgrades Cray to Hold, but says bidding war possible
Craig-Hallum analyst Chad Bennett downgrade Cray (CRAY) to Hold from Buy after the company announced a deal to be acquired by HP Enterprise (HPE) for $35 per share, but he added that he thinks a bidding war is possible since he doesn't believe the stock buyout price "has even begun to value" Cray's proprietary interconnect technology and its modular software stack for next generation AI/ML workloads. He believes there could be a number of interested parties in Cray including Microsoft (MSFT), Dell (DELL), Intel (INTC), Google (GOOG), Amazon (AMZN) and potentially IBM (IBM).
05/17/19
WELS
05/17/19
DOWNGRADE
WELS
Market Perform
Cray downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded Cray (CRAY) to Market Perform from Outperform with an unchanged price target of $35 after the company reached a deal to be acquired by HP Enterprise (HPE). The firm, however, expects some investors to question why Cray shouldn't be able to command a higher premium than $35 per share given the recovery in the high-end supercomputing market.
DVAX Dynavax
$6.36

(0.00%)

02/27/19
CANT
02/27/19
NO CHANGE
Target $28
CANT
Overweight
Dynavax price target raised to $28 from $23 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Dynavax Technologies to $28 following the company's financial and corporate updates from Q4. The analyst is encouraged by the first HEPLISAV-B launch year and expects updates from the SD-101 program to be a key focus for investors during 2019. He reiterates an Overweight rating on Dynavax.
10/22/18
JPMS
10/22/18
NO CHANGE
Target $27
JPMS
Overweight
JPMorgan expects 35%-50% rally in Dynavax after 'clear win' data
JPMorgan analyst Anupam Rama views Dynavax Technologies' update to the SD-101 plus pembrolizumab combination program as a "clear win." The analyst's focus is on the treatment naive melanoma data set, given that the presentation has the most patients at the go-forward 2mg dose level. These data hit the analyst's "upside / homerun scenario" with a 70% overall response rate. Rama sees Dynavax shares trading up in the 35%-50% range following this weekend's update. He keeps an Overweight rating on the name with a $27 price target. The stock in premarket trading is up 21%, or $2.26, to $13.15.
10/22/18
RBCM
10/22/18
NO CHANGE
Target $26
RBCM
Outperform
Dynavax price target raised to $26 from $23 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Dynavax to $26 and kept his Outperform rating after its PD-1 melanoma presentations at the European Society for Medcal Oncology Congress this weekend. The analyst notes that the findings revealed no new safety signals and continued abscopal responses across both PD-L1 positive and negative patients, which he views as the "best-case scenario for this data cut".
10/22/18
CANT
10/22/18
NO CHANGE
Target $32
CANT
Overweight
Dynavax price target raised to $32 from $30 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Dynavax Technologies (DVAX) to $32 following presentations at the European Society for Medical Oncology Congress. The data present the case for why Merck (MRK) could be a potential partner, Piros tells investors in a research note. He keeps an Overweight rating on Dynavax.
RTIX RTI Surgical
$4.40

-0.08 (-1.79%)

TODAY'S FREE FLY STORIES

BPMX

BioPharmX

$0.85

-0.0563 (-6.22%)

07:31
06/25/19
06/25
07:31
06/25/19
07:31
Hot Stocks
BioPharmX announces results from Phase 2b clinical trial of BPX-041 »

BioPharmX announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

MEET

Meet Group

$3.31

-0.265 (-7.42%)

, AAPL

Apple

$198.60

-0.17 (-0.09%)

07:31
06/25/19
06/25
07:31
06/25/19
07:31
Recommendations
Meet Group, Apple, Alphabet, Alphabet Class A analyst commentary  »

Meet Group should be able…

MEET

Meet Group

$3.31

-0.265 (-7.42%)

AAPL

Apple

$198.60

-0.17 (-0.09%)

GOOG

Alphabet

$1,115.75

-6.63 (-0.59%)

GOOGL

Alphabet Class A

$1,117.00

-8.17 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 25

    Jul

  • 27

    Oct

AKRX

Akorn

$4.71

-0.06 (-1.26%)

07:30
06/25/19
06/25
07:30
06/25/19
07:30
Hot Stocks
Breaking Hot Stocks news story on Akorn »

Akorn trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$41.15

11.87 (40.54%)

07:30
06/25/19
06/25
07:30
06/25/19
07:30
Recommendations
Krystal Biotech analyst commentary  »

Krystal Biotech price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

ETFC

E-Trade

$44.57

-1.66 (-3.59%)

07:30
06/25/19
06/25
07:30
06/25/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

ALDX

Aldeyra

$7.08

-0.29 (-3.93%)

07:30
06/25/19
06/25
07:30
06/25/19
07:30
Hot Stocks
Breaking Hot Stocks news story on Aldeyra 

Aldeyra trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$30.51

-0.98 (-3.11%)

07:26
06/25/19
06/25
07:26
06/25/19
07:26
Periodicals
Buffett denies reports of tension between him, 3G over Kraft Heinz, CNBC reports »

Buffett says 3G's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$223.66

1.76 (0.79%)

07:26
06/25/19
06/25
07:26
06/25/19
07:26
Recommendations
Tesla analyst commentary  »

Oppenheimer continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$72.05

0.91 (1.28%)

, MCD

McDonald's

$203.92

-0.29 (-0.14%)

07:26
06/25/19
06/25
07:26
06/25/19
07:26
Upgrade
GrubHub, McDonald's, Starbucks rating change  »

Citi sees five reasons to…

GRUB

GrubHub

$72.05

0.91 (1.28%)

MCD

McDonald's

$203.92

-0.29 (-0.14%)

SBUX

Starbucks

$83.65

-0.16 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 26

    Jul

ERI

Eldorado Resorts

$45.86

-5.36 (-10.46%)

07:25
06/25/19
06/25
07:25
06/25/19
07:25
Conference/Events
Eldorado Resorts to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

BPOP

Popular

$52.70

0.37 (0.71%)

07:23
06/25/19
06/25
07:23
06/25/19
07:23
Recommendations
Popular analyst commentary  »

Popular's valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

MYGN

Myriad Genetics

$23.04

-0.47 (-2.00%)

07:23
06/25/19
06/25
07:23
06/25/19
07:23
Hot Stocks
Myriad Genetics announces publication of EndoPredict cost effectiveness study »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 06

    Aug

  • 13

    Nov

HEXO

HEXO Corp

$5.35

-0.245 (-4.38%)

07:20
06/25/19
06/25
07:20
06/25/19
07:20
Downgrade
HEXO Corp rating change  »

HEXO Corp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVXL

Anavex

$3.25

-0.12 (-3.56%)

07:20
06/25/19
06/25
07:20
06/25/19
07:20
Hot Stocks
Anavex announces first patient dosed in Rett syndrome extension study »

Anavex announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANGI

Angi Homeservices

$14.38

-0.21 (-1.44%)

07:19
06/25/19
06/25
07:19
06/25/19
07:19
Recommendations
Angi Homeservices analyst commentary  »

Angi Homeservices price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

BHF

Brighthouse Financial

$38.10

-0.01 (-0.03%)

07:19
06/25/19
06/25
07:19
06/25/19
07:19
Downgrade
Brighthouse Financial rating change  »

Brighthouse Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGTC

Applied Genetic

$3.80

-0.145 (-3.68%)

, AERI

Aerie Pharmaceuticals

$30.21

-0.7 (-2.26%)

07:18
06/25/19
06/25
07:18
06/25/19
07:18
Hot Stocks
Applied Genetic names Theresa Heah CMO, Brian Krex general counsel »

Applied Genetic (AGTC)…

AGTC

Applied Genetic

$3.80

-0.145 (-3.68%)

AERI

Aerie Pharmaceuticals

$30.21

-0.7 (-2.26%)

ALXN

Alexion

$126.92

-5.55 (-4.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 10

    Jul

  • 11

    Jul

  • 31

    Jul

  • 01

    Aug

MCHP

Microchip

$85.16

0.08 (0.09%)

07:16
06/25/19
06/25
07:16
06/25/19
07:16
Initiation
Microchip initiated  »

Microchip initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLAB

Silicon Labs

$96.26

-0.41 (-0.42%)

07:14
06/25/19
06/25
07:14
06/25/19
07:14
Initiation
Silicon Labs initiated  »

Silicon Labs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNC

Lincoln National

07:14
06/25/19
06/25
07:14
06/25/19
07:14
Upgrade
Lincoln National rating change  »

Lincoln National upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

TRI

Thomson Reuters

$65.83

-0.16 (-0.24%)

07:13
06/25/19
06/25
07:13
06/25/19
07:13
Downgrade
Thomson Reuters rating change  »

Thomson Reuters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$39.80

-1.26 (-3.07%)

07:13
06/25/19
06/25
07:13
06/25/19
07:13
Recommendations
Biohaven Pharmaceutical analyst commentary  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

SHW

Sherwin-Williams

$465.88

0.225 (0.05%)

07:13
06/25/19
06/25
07:13
06/25/19
07:13
Downgrade
Sherwin-Williams rating change  »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

ARVN

Arvinas

$21.81

(0.00%)

07:12
06/25/19
06/25
07:12
06/25/19
07:12
Hot Stocks
Arvinas announces FDA clearance of ARV-471 IND »

Arvinas announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$91.86

-1.78 (-1.90%)

07:11
06/25/19
06/25
07:11
06/25/19
07:11
Downgrade
Tiffany rating change  »

Tiffany SSS may prove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.